These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20881220)

  • 1. Missing data in model-based pharmacometric applications: points to consider.
    Gastonguay MR; French JL; Heitjan DF; Rogers JA; Ahn JE; Ravva P
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):63S-74S. PubMed ID: 20881220
    [No Abstract]   [Full Text] [Related]  

  • 2. The need for modeling and simulation to design clinical investigations in children.
    Jadhav PR; Kern SE
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):121S-129S. PubMed ID: 20881225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization concepts to enhance quantitative decision making in drug development.
    Dykstra K; Pugh R; Krause A
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):130S-139S. PubMed ID: 20881226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing model diagnostics.
    Karlsson MO; Savic RM
    Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missing data? Plan on it!
    Palmer RF; Royall DR
    J Am Geriatr Soc; 2010 Oct; 58 Suppl 2():S343-8. PubMed ID: 21029065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 7. Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.
    Song JX
    Pharm Stat; 2006; 5(4):295-304. PubMed ID: 17128429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A point estimator for the time course of drug release.
    Koehne-Voss S; Pigeot I
    Biom J; 2009 Feb; 51(1):146-58. PubMed ID: 19219906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
    Dallow NS; Leonov SL; Roger JH
    Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Note in statistical treatment of medical and pharmaceutical data.
    Kawase M; Konishi H; Yagi K; Nishikiori R; Takagi T
    J Biosci Bioeng; 2005 Jul; 100(1):116-8. PubMed ID: 16233861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
    de Leon J; Spina E; Diaz FJ
    J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
    [No Abstract]   [Full Text] [Related]  

  • 19. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expected estimating equations for missing data, measurement error, and misclassification, with application to longitudinal nonignorable missing data.
    Wang CY; Huang Y; Chao EC; Jeffcoat MK
    Biometrics; 2008 Mar; 64(1):85-95. PubMed ID: 17608787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.